> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Origin Biosciences Wins Priority Review Voucher
- URL: https://www.fdaweb.com/origin-biosciences-wins-priority-review-voucher/
- Published: 2021-03-11T12:00:00.000Z
- Updated: 2026-09-14T16:50:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148859

*Federal Register* notice: FDA has announced its issuance of a priority review voucher to Origin Biosciences after it gained approval for a qualified rare pediatric disease product application —Nulibry (fosdenopterin). The drug is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-05207.pdf?ref=fdaweb.com).